Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope
AssigneeB.R.A.H.M.S GmbH
InventorsJoachim Struck, Olle Melander, Artur Fedorowski
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope in a patient the method comprising: determining the level of at least one biomarker selected from the group consisting of proET-1, pro ADM, proANP, proBNP, proAVP and PCT or a fragment of at least 12 amino acids thereof, in a sample of a bodily fluid of said patient, correlating said level of at least one biomarker or fragments thereof with the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope.
Claims22
A method for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope in a patient the method comprising:
- determining the level of at least one biomarker selected from the group consisting of proET-1, proADM, proANP, proBNP, proAVP and PCT or a fragment of at least 12 amino acids thereof, in a sample of a bodily fluid of said patient,
- correlating said level of at least one biomarker or fragments thereof with the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope.
The use of one or more biomarkers selected from the group consisting of proADM, proANP, proBNP, proAVP, proET-1 and PCT or a fragment of at least 12 amino acids thereof for the diagnosis and/or prognosis and/or assessment and/or therapy stratification of syncope.
Dependencies are inferred from the claim text.